Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q2 2024 (← Previous) (Next →)

Filing Date: Aug 14, 2024

Total Value ($000): $306,704 (100.0% shares, 0.0% debt)

Holdings (7)

MDXG MIMEDX GROUP, INC. 63.7%

Value ($000) $195,393 Shares 28,195,249 Est. Cost $7.32 Unrealized -4.0%

BVS BIOVENTUS 24.4%

Value ($000) $74,873 Shares 13,021,324 Est. Cost $13.37 Unrealized -59.0%

TELA TELA BIO, INC. 6.3%

Value ($000) $19,320 Shares 4,110,709 Est. Cost $11.82 Unrealized -55.4%

EYPT EYEPOINT PHARMACEUTICALS INC 4.4%

Value ($000) $13,498 Shares 1,551,521 Est. Cost $4.68 Unrealized +198.4%

MNOV MEDICINOVA INC 0.5%

Value ($000) $1,593 Shares 1,105,941 Est. Cost $2.95 Unrealized -52.5%

— REVANCE THERAPEUTICS INC 0.4%

Value ($000) $1,175 Shares 457,085 Est. Cost $31.50 Unrealized —

— VENUS CONCEPT, INC. 0.3%

Value ($000) $853 Shares 1,089,190 Est. Cost $0.69 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
MDXG	MIMEDX GROUP, INC.	28,195,249	$195,393	63.7%	$7.32	-4.0%	COM	602496101
BVS	BIOVENTUS	13,021,324	$74,873	24.4%	$13.37	-59.0%	COM CL A	09075A108
TELA	TELA BIO, INC.	4,110,709	$19,320	6.3%	$11.82	-55.4%	COM	872381108
EYPT	EYEPOINT PHARMACEUTICALS INC	1,551,521	$13,498	4.4%	$4.68	+198.4%	COM NEW	30233G209
MNOV	MEDICINOVA INC	1,105,941	$1,593	0.5%	$2.95	-52.5%	COM NEW	58468P206
—	REVANCE THERAPEUTICS INC	457,085	$1,175	0.4%	$31.50	—	COM	761330109
—	VENUS CONCEPT, INC.	1,089,190	$853	0.3%	$0.69	—	COM	92332W204